Live cell encapsulation Market Analysis

Live Cell Encapsulation Market Analysis

To get key market trends

  Download Free Sample

Based on polymer type, the live cell encapsulation market is segmented as natural polymers and synthetic polymers. The natural polymers segment further divided into alginate, chitosan, cellulose, and others. The natural polymers segment held a majority market value of USD 177.5 million in 2022. Natural polymers are large-molecular-weight macromolecules sourced from nature and are preferred because they are non-toxic, biodegradable, renewable, biocompatible, and adaptable to changes. Such benefits associated with natural polymers made it the key choice for cell encapsulation. Since they have a natural origin, such as bacteria, animals, and plants, they can interact with cells and tissues by displaying characteristics that the body recognises and as a result, they does not perceive them as foreign objects. Thus, to transport and deliver hydrophobic or hydrophilic active components, which may be in solid, liquid, or gaseous phases, to the needed places, natural polymers, such as lipids, proteins, and polysaccharides have been used as an encapsulation.
 

Based on method, live cell encapsulation market is segmented as microencapsulation, macroencapsulation, and nanoencapsulation. The microencapsulation held a dominant market share of around 66.8% in 2022 and is expected to grow at a significant pace during the analysis period. Microencapsulation is a formulation process that encapsulates bioactive substances at particle sizes ranging from 1 to 1000 μm in diameter for controlled and sustained delivery and protection of the bioactive compound protected from the surrounding environment. This method comprises various applications in the treatment of diseases such as cancer, tuberculosis, rheumatoid arthritis, diabetes, and respiratory infections. For instance, the islets of Langerhans are microencapsulated and implanted for the long-term treatment of diabetes or another disease requiring an organ transplant. Thus, increasing therapeutic applications of the microencapsulation method is anticipated to foster the market statistics.
 

Based on application, the live cell encapsulation market is segmented as drug delivery, regenerative medicine, cell transplantation, and others. The drug delivery segment held a dominant market share in 2022 and is expected to grow at a significant pace of 4.3% between 2023 to 2032. Live cell encapsulation technique is used in the manufacturing of tablets, capsules, and parenteral dosage forms for efficient drug delivery. Controlled drug delivery comprises great potential in many diseases with deteriorative progression. Therefore, the benefits of controlled drug delivery by living cell encapsulation, such as reduced drug dose, improved therapeutic efficacy, improved patient compliance and convenience, reduced cytotoxicity, is accelerating the segmental growth. Furthermore, growing research programs to determine the clinical efficacy of the live cell encapsulation process, is anticipated to supplement the market growth.
 

U.S. live cell encapsulation market value surpassed USD 79.4 million in 2022. This majority market share is attributable to the increasing prevalence of diabetes. For instance, according to the National Diabetes Statistics Report 2022, more than 37 million people of all ages (11.3% of the U.S. population) had diabetes, but 8.5 million adults (23% of adults with diabetes) were not aware of having diabetes. Among those aged 65 years or older, the percentage of adults with diabetes increased to 29.2%. Thus, the growing number of diabetes cases creates a great opportunity for market participants to provide a new live cell encapsulated drug to treat people with diabetes, which is expected to promote market expansion.
 

Additionally, presence of key operating players coupled with increasing clinical trial studies for product launch will supplement the regional growth. For instance, in February 2021, ViaCyte, Inc. announced the initiation of phase 2 clinical study of encapsulated cell therapy for type 1 diabetes patients. Such factor is expected to proliferate the regional market growth.